MX2021015492A - Conjugados de un resto de interleucina-15 (il-15) y un polimero. - Google Patents

Conjugados de un resto de interleucina-15 (il-15) y un polimero.

Info

Publication number
MX2021015492A
MX2021015492A MX2021015492A MX2021015492A MX2021015492A MX 2021015492 A MX2021015492 A MX 2021015492A MX 2021015492 A MX2021015492 A MX 2021015492A MX 2021015492 A MX2021015492 A MX 2021015492A MX 2021015492 A MX2021015492 A MX 2021015492A
Authority
MX
Mexico
Prior art keywords
conjugates
moiety
polymer
nonpeptidic
methods
Prior art date
Application number
MX2021015492A
Other languages
English (en)
Inventor
Xiaofeng Liu
Peter Benedict Kirk
Thomas Chang
Deborah H Charych
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2021015492A publication Critical patent/MX2021015492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan conjugados de un resto de IL-15 y uno o más polímeros hidrosolubles no peptídicos; normalmente, el polímero hidrosoluble no peptídico es poli(etilenglicol) o un derivado de éste; también se proporcionan, entre otras cosas, composiciones que comprenden los conjugados, métodos para preparar los conjugados y métodos para administrar las composiciones a un individuo.
MX2021015492A 2014-04-03 2016-09-30 Conjugados de un resto de interleucina-15 (il-15) y un polimero. MX2021015492A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03

Publications (1)

Publication Number Publication Date
MX2021015492A true MX2021015492A (es) 2022-02-22

Family

ID=54241432

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012908A MX2016012908A (es) 2014-04-03 2015-04-01 Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2021015492A MX2021015492A (es) 2014-04-03 2016-09-30 Conjugados de un resto de interleucina-15 (il-15) y un polimero.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016012908A MX2016012908A (es) 2014-04-03 2015-04-01 Conjugados de un resto de interleucina-15 (il-15) y un polimero.

Country Status (12)

Country Link
US (1) US20170035898A1 (es)
EP (2) EP3919071A1 (es)
JP (2) JP6728055B2 (es)
KR (1) KR102432169B1 (es)
CN (1) CN106456716A (es)
AU (3) AU2015240806B2 (es)
CA (1) CA2942571C (es)
ES (1) ES2876433T3 (es)
IL (1) IL248169A0 (es)
MA (1) MA39711A (es)
MX (2) MX2016012908A (es)
WO (1) WO2015153753A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
MA47290A (fr) * 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
KR20180089516A (ko) * 2015-12-21 2018-08-08 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CA3060410A1 (en) * 2017-05-15 2018-11-22 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CA3091857A1 (en) * 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
EP3876974A4 (en) * 2018-11-09 2022-11-23 Nektar Therapeutics LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT
KR20220004134A (ko) * 2019-04-26 2022-01-11 프로린크스 엘엘시 서방형 사이토카인 컨쥬게이트
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
JP2022544817A (ja) * 2019-08-23 2022-10-21 シンソークス， インコーポレイテッド Ｉｌ－１５コンジュゲートおよびその使用
CN117355337A (zh) * 2021-03-29 2024-01-05 奥迪曼药业科技有限公司 蛋白-大分子缀合物及其使用方法
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
EP4370536A2 (en) * 2021-07-12 2024-05-22 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
EP0728210B1 (en) * 1993-11-12 2005-04-13 Gilead Sciences, Inc. Thrombin mutants
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE196315T1 (de) 1994-04-06 2000-09-15 Immunex Corp Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
JP4490290B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
ATE485331T1 (de) 2003-01-06 2010-11-15 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
CA2538083A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
AR050693A1 (es) * 2004-08-11 2006-11-15 Zheng Xin Xiao Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
CA2583274A1 (en) 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
RS53968B1 (en) 2005-06-16 2015-08-31 Nektar Therapeutics CONJUGATES WHICH HAVE A COUPLING WHICH MAY BE DEGRADED AND POLYMER REAGENTS USED FOR THE PREPARATION OF SUCH CONJUGATES
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINS AND COMPOSITIONS CONTAINING THEREOF
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
SI2598172T1 (sl) * 2010-07-30 2019-08-30 Baxalta GmbH Nukleofilni katalizatorji za oksimsko vezavo
CA3144697A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Also Published As

Publication number Publication date
CN106456716A (zh) 2017-02-22
MA39711A (fr) 2015-10-08
KR20170005793A (ko) 2017-01-16
AU2015240806B2 (en) 2019-09-19
JP2017511322A (ja) 2017-04-20
EP3139947A4 (en) 2018-01-17
JP2020114875A (ja) 2020-07-30
AU2019283778A1 (en) 2020-01-16
AU2021258008A1 (en) 2021-11-25
CA2942571C (en) 2023-09-19
MX2016012908A (es) 2017-01-11
EP3139947B8 (en) 2021-06-30
WO2015153753A3 (en) 2015-11-26
EP3919071A1 (en) 2021-12-08
KR102432169B1 (ko) 2022-08-11
JP6728055B2 (ja) 2020-07-22
ES2876433T3 (es) 2021-11-12
EP3139947A2 (en) 2017-03-15
CA2942571A1 (en) 2015-10-08
IL248169A0 (en) 2016-11-30
WO2015153753A2 (en) 2015-10-08
EP3139947B1 (en) 2021-05-26
US20170035898A1 (en) 2017-02-09
AU2015240806A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MX2021015492A (es) Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2017011562A (es) Conjugados de un resto de il-7 y un polimero.
MX2017002333A (es) Conjugados novedosos de glicano y uso de los mismos.
EP3393500A4 (en) POLYMER CONJUGATES WITH REDUCED ANTIGENICITY AND METHOD FOR USE THEREOF
WO2016040369A3 (en) HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
SG10201909805XA (en) Surface modified polymer compositions
MX358399B (es) Conjugados de un resto de interleucina-2 y un polímero.
MX2016009943A (es) Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares.
PH12017500555A1 (en) Modified phosphpors and compositions thereof
EP3037475A4 (en) Phenoxy cyclotriphosphazene active ester, halogen-free resin composition and use thereof
WO2015168225A3 (en) Alkoxy polycarbonates, bisphenol monomers and methods of making and using the same
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
EP4252681A3 (en) Implantable objects, guiding devices, and methods of use thereof
MX2013007230A (es) Sistemas de polimero.
MX2016004885A (es) Composicion de polimero funcionalizado.
MY192958A (en) Mixed decyl mercaptans compositions and methods of making same
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2019009604A (es) Composicion quimica.
TW201614007A (en) Composition for forming silica layer, silica layer, and electronic device
WO2013020079A3 (en) Conjugates of an il-11 moiety and a polymer
MX2017000497A (es) Detergente en tableta para lavavajillas y metodos de fabricacion y de utilizacion del mismo.
MX2016010229A (es) Conjugados del factor vii.
EP3445899A4 (en) FINE FIBERS WITH LOW MOLECULAR WEIGHT OR HIGH MOLECULAR WEIGHT AND FIBER FINE TPU